首页 | 本学科首页   官方微博 | 高级检索  
   检索      


Glycerophospholipids and glycerophospholipid-derived lipid mediators: a complex meshwork in Alzheimer's disease pathology
Authors:Frisardi Vincenza  Panza Francesco  Seripa Davide  Farooqui Tahira  Farooqui Akhlaq A
Institution:aDepartment of Geriatrics, Center for Aging Brain, Memory Unit, University of Bari, Bari, Italy;bGeriatric Unit and Gerontology, Geriatric Research Laboratory, IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy;cDepartment of Molecular and Cellular Biochemistry, The Ohio State University, Columbus, OH, USA
Abstract:An increasing body of evidence suggested that intracellular lipid metabolism is dramatically perturbed in various cardiovascular and neurodegenerative diseases with genetic and lifestyle components (e.g., dietary factors). Therefore, a lipidomic approach was also developed to suggest possible mechanisms underlying Alzheimer’s disease (AD). Neural membranes contain several classes of glycerophospholipids (GPs), that not only constitute their backbone but also provide the membrane with a suitable environment, fluidity, and ion permeability. In this review article, we focused our attention on GP and GP-derived lipid mediators suggested to be involved in AD pathology. Degradation of GPs by phospholipase A2 can release two important brain polyunsaturated fatty acids (PUFAs), e.g., arachidonic acid and docosahexaenoic acid, linked together by a delicate equilibrium. Non-enzymatic and enzymatic oxidation of these PUFAs produces several lipid mediators, all closely associated with neuronal pathways involved in AD neurobiology, suggesting that an interplay among lipids occurs in brain tissue. In this complex GP meshwork, the search for a specific modulating enzyme able to shift the metabolic pathway towards a neuroprotective role as well as a better knowledge about how lipid dietary modulation may act to slow the neurodegenerative processes, represent an essential step to delay the onset of AD and its progression. Also, in this way it may be possible to suggest new preventive or therapeutic options that can beneficially modify the course of this devastating disease.
Keywords:Abbreviations: 2-AG  2-arachidonoylglycerol  4-HNE  4-hydroxynonenals  4-HHE  4-hydroxyhexenal  AA  arachidonic acid    β-amyloid  ADAM  A Disintegrin And Metalloprotease  ADAPT  Alzheimer&rsquo  s Disease Anti-inflammatory Prevention trial  AD  Alzheimer&rsquo  s disease  AEA  arachidonyl-ethanolamide (anandamide)  APP  amyloid precursor protein  BACE1  β-site APP cleavage enzyme  BAD  BCL-2-associated death promoter  BAX  BCL-2-associated X protein  BBB  blood&ndash  brain barrier  BCL-2  B-cell lymphoma 2  BDNF  brain-derived neurotrophic factor  CA1  cornu ammonius 1  CB1  cannabinoid receptors of type 1  CB2  cannabinoid receptors of type 2  CNS  central nervous system  COX  cyclooxygenase  cPLA2  cytosolic phospholipase A2  DHA  docosahexaenoic acid  EC  endocannabinoid  EPA  eicosapentaenoic acid  EPOX  epoxygenases  ER  endoplasmic reticulum  ERK  extracellular signal-regulated kinase  FAAH  fatty acid amidohydrolase  GP  glycerophospholipid  CSF  cerebrospinal fluid  GSK-3  glycogen synthase kinase 3  HETE  hydroxyeicosatetraenoic acid  isoF  isofuran  isoK  isoketal  isoP  isoprostane  IL  interleukin  JNK/SAPK  c-Jun N-terminal kinase/stress-activated protein kinase  LA  linoleic acid  LC-ESI-MS  liquid chromatography electrospray ionization mass spectrometry  LC-FACS  long-chain fatty acyl-CoA synthetase  LOX  lipoxygenases  LPA  lysophosphatidic acid  LPC  lysophosphatidylcholine  LPE  lysophosphatidylethanolamine  LPI  lysophosphatidylinositol  LPS  lysophosphatidylserine  LT  leukotriene  LTP  long term potentiation  LX  lipoxin  MAPK  mitogen-activated protein kinase  MCI  mild cognitive impairment  MDA  malondialdehyde  mGluR  metabotropic glutamate receptor  MaR  maresin  NF-kB  nuclear factor-kappa B  NF  neurofuran  NFT  neurofibrillary tangle  NK  neuroketal  NMDA  d-aspartate" target="_blank">N-methyl-d-aspartate  NMDAR  d-aspartate glutamate receptor subtype" target="_blank">N-methyl-d-aspartate glutamate receptor subtype  NOS  nitric oxide synthase  NP  neuroprostane  NP  neuroprotectin  NSAID  non-steroidal anti-inflammatory drug  PAF  platelet activating factor  PAFR  platelet activator factor receptor  PC  phosphatidylcholine  PE  phosphatidylethanolamine  PKC  protein kinase C  PLA2  phospholipase A2  PG  prostaglandin  PI  phosphatidylinositol  PMN  polymorphonuclear neutrophils  PPAR  peroxisome proliferator-activated receptor  PUFA  polyunsaturated fatty acid  RAR  retinoic acid receptor  rCBF  regional cerebral blood flow  ROS  reactive oxygen species  RPE  retinal pigment epithelium  Rv  resolvin  RXR  retinoid X receptor  SP  senile plaque  sPLA2  secretory phospholipase A2  TNF-α  tumor necrosis factor-α  TRPV1  transient receptor potential vanilloid 1  TX  thromboxane
本文献已被 ScienceDirect PubMed 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号